# Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

> **NCT01319981** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 31 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Imatinib
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Mesna
- **DRUG:** VSLI
- **DRUG:** Solu-Medrol
- **DRUG:** Methotrexate
- **DRUG:** Ara-C
- **DRUG:** G-CSF
- **DRUG:** Pegfilgrastim
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01319981
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-05
- **Primary completion:** 2020-11-11
- **Final completion:** 2020-11-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01319981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01319981, "Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01319981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*